본문으로 건너뛰기
← 뒤로

Deep cytomorphology identifies erythroid skewing and monocytic morphology to predict TKI sensitivity in CML patients.

1/5 보강
HemaSphere 📖 저널 OA 100% 2021: 1/1 OA 2025: 17/17 OA 2026: 41/41 OA 2021~2026 2026 Vol.10(2) p. e70319 OA
Retraction 확인
출처

PICO 자동 추출 (휴리스틱, conf 2/4)

유사 논문
P · Population 대상 환자/모집단
598 patients across seven sites using deep learning-based image analysis to identify cytomorphological markers predictive of major molecular response.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Notably, poor-risk patients treated with second-generation TKIs achieved outcomes similar to favorable-risk patients on imatinib. These results underline the overlooked prognostic value of BM cytomorphology to refine risk stratification and support more personalized frontline therapy in CML.

Luukkainen K, Purhonen M, Tatun M, Hung K, Tafjord O, Sundquist H

📝 환자 설명용 한 줄

The cellular composition of the chronic myeloid leukemia (CML) bone marrow (BM) beyond granulocyte enrichment remains poorly understood.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Luukkainen K, Purhonen M, et al. (2026). Deep cytomorphology identifies erythroid skewing and monocytic morphology to predict TKI sensitivity in CML patients.. HemaSphere, 10(2), e70319. https://doi.org/10.1002/hem3.70319
MLA Luukkainen K, et al.. "Deep cytomorphology identifies erythroid skewing and monocytic morphology to predict TKI sensitivity in CML patients.." HemaSphere, vol. 10, no. 2, 2026, pp. e70319.
PMID 41694735 ↗
DOI 10.1002/hem3.70319

Abstract

The cellular composition of the chronic myeloid leukemia (CML) bone marrow (BM) beyond granulocyte enrichment remains poorly understood. We analyzed 1548 routinely stained BM aspirate slides from 598 patients across seven sites using deep learning-based image analysis to identify cytomorphological markers predictive of major molecular response. Erythroid precursor enrichment, monocyte nuclear lobulation, and low peripheral leukocyte count were associated with improved tyrosine kinase inhibitor (TKI) response. These features were validated both visually and computationally in two independent cohorts. We developed a Morphoclinical model integrating these image-derived and clinical variables, outperforming (area under the receiver-operating curve [AUROC] 0.76) the clinically used EUTOS long-term survival score (AUROC 0.53) and halving time (AUROC 0.61). Notably, poor-risk patients treated with second-generation TKIs achieved outcomes similar to favorable-risk patients on imatinib. These results underline the overlooked prognostic value of BM cytomorphology to refine risk stratification and support more personalized frontline therapy in CML.
🟢 PMC 전문 열기